Ashley B. Pitcher

  • Citations Per Year
Learn More
In most developed countries, HCV is primarily transmitted by injecting drug users (IDUs). HCV antiviral treatment is effective, and deemed cost-effective for those with no re-infection risk. However, few active IDUs are currently treated. Previous modelling studies have shown antiviral treatment for active IDUs could reduce HCV prevalence, and there is(More)
MARTIN B. SHORT, ASHLEY B. PITCHER and MARIA R. D’ORSOGNA 1Mathematics Department, UCLA, Los Angeles, CA 90095-1555, USA email: mbshort@math.ucla.edu 2Centre d’Analyse et de Mathématique Sociales, Ecole des Hautes Etudes en Sciences Sociales, 190-198 Avenue de France, Paris cedex 13, France 75244 email: ashley.pitcher@balliol.oxon.org 3Mathematics(More)
The lack of head-to-head clinical studies powered to compare atomoxetine and osmotic release oral system (OROS) methylphenidate necessitates treatment comparison by methods that include indirect evidence such as network meta-analysis (NMA). A NMA assessing the relative treatment effects of atomoxetine and OROS methylphenidate in adults with(More)
◾ Patient baseline characteristics were taken from the relevant CANA trial in that setting. Treatment effects also came from these trials, with the exception of the comparison to SITA in triple therapy and with DAPA as an add-on to insulin, where treatment effects were taken from the results of a network meta-analysis (NMA; Pacou et al22 and data on file)(More)
OBJECTIVE To assess the cost-effectiveness of subcutaneous interferon (sc IFN) beta-1a 44 mcg 3-times weekly (tiw) vs no treatment at reducing the risk of conversion to multiple sclerosis (MS) in patients with clinically isolated syndrome (CIS) in Sweden. METHODS A Markov model was constructed to simulate the clinical course of patients with CIS treated(More)
OBJECTIVES This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK, Italy, and Spain. METHODS Efficacy and safety outcomes were obtained from GetGoal Duo-2, a 26-week phase 3 trial comparing(More)